title: Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002.
abstract: Monitoring of serotypes and their clonal associations is critical as pneumococci adapt to the selective pressures exerted by the pneumococcal seven-valent conjugate vaccine (PCV7). We genotyped 1,476 invasive isolates from the Active Bacterial Core surveillance (705 [89.8%] of the isolates were obtained from children <5 years of age, and 771 [18.4%] of the isolates were obtained from individuals >5 years of age) in 2001 and 2002 (after the introduction of PCV7). The data were compared to the results for 1,168 invasive isolates (855 [83.9%] of the isolates were from children <5 years of age) collected in 1999. Among children <5 years of age, the incidence of invasive disease due to non-PCV7 serogroups together with serogroup 19A increased (P < 0.001). Eighty-three clonal sets, representing 177 multilocus sequence types (STs), were compiled from the 3-year isolate set. Among the non-PCV7 serogroups, newly emerging clones were uncommon; and a significant expansion of already established clones occurred for serotypes 3 (ST180), 7F (ST191), 15BCF (ST199), 19A (ST199), 22F (ST433), 33F (ST662), and 38 (ST393). However, additional minor clonal types within serotypes 1, 6A, 6B, 7C, 9N, 10A, 12F, 14, 15B/C, 17F, 19A, 19F, 20, 22F, and 33F that were absent in 1999 were found during 2001 and 2002. Although 23 clonal sets exhibited multiple serotypes, for most serotypes there were either no changes or modest changes in clonal compositions since the introduction of PCV7. The only example of an identical ST shared between non-PCV7 and PCV7 or PCV7-related serotypes was ST199; however, ST199 was prevalent within serotypes 15B/C and 19A before and after PCV7 introduction. Continued genotypic surveillance is warranted, since certain clones not targeted by PCV7 are expanding, and their emergence as significant pathogens could occur with maintained vaccine pressure.
authors.affiliation: Repsiratory Diseases Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd., NE, Mailstop C02, Atlanta, Georgia 30333, USA. BBEALL@CDC.GOV
authors.forename: Bernard
authors.initials: B
authors.lastname: Beall
authors.forename: M Catherine
authors.initials: MC
authors.lastname: McEllistrem
authors.forename: Robert E
authors.initials: RE
authors.lastname: Gertz
authors.forename: Stephanie
authors.initials: S
authors.lastname: Wedel
authors.forename: David J
authors.initials: DJ
authors.lastname: Boxrud
authors.forename: Antonio L
authors.initials: AL
authors.lastname: Gonzalez
authors.forename: Marie-Jo
authors.initials: MJ
authors.lastname: Medina
authors.forename: Rekha
authors.initials: R
authors.lastname: Pai
authors.forename: Terry A
authors.initials: TA
authors.lastname: Thompson
authors.forename: Lee H
authors.initials: LH
authors.lastname: Harrison
authors.forename: Lesley
authors.initials: L
authors.lastname: McGee
authors.forename: Cynthia G
authors.initials: CG
authors.lastname: Whitney
mesh_terms: D000328:Adult; D002675:Child, Preschool; D024881:Drug Resistance, Bacterial; D005838:Genotype; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D017720:Molecular Epidemiology; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000008:administration & dosage*; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification* / Q000187:drug effects / Q000302:isolation & purification* / Q000472:pathogenicity; D013997:Time Factors; D014481:United States / Q000453:epidemiology
chemical_list: D022242:Pneumococcal Vaccines